Livagen Dosage Guide: Protocols, Calculator & Safety

Dose Range

10 mg oral capsule, 1-2 daily for 10-30 days

Stacking Notes

Livagen is most commonly encountered in Khavinson-style "organ-specific bioregulator" stacks, where several tetrapeptides (Livagen for liver, Pinealon for brain, Vilon for immune/thymus, Thymogen for thymus, Epitalon for pineal) are cycled together or sequentially. We describe how this is typically done, assess the evidence behind it, and point to stacking options with stronger mechanistic rationale.

Khavinson multi-bioregulator cycles

Within the Russian longevity community, Livagen is commonly run as part of a rotating bioregulator programme — e.g., Livagen + Epitalon + Pinealon cycled for 10 days, followed by a washout, followed by a different combination. The theoretical argument is that different tetrapeptides modulate different target tissues and their effects are additive or synergistic. No controlled experiments confirm synergy; the pattern rests on Khavinson's framework rather than head-to-head data.

If you are going to follow this pattern, the conservative execution is:

• Livagen 20 mg daily oral/sublingual x 10 days as a stand-alone liver-targeted cycle
• Then 60–90 days washout
• Then Epitalon 5–10 mg subcutaneous x 10 days for pineal/general-aging
• Then washout
• Then another Livagen cycle if desired

Cycling rather than continuous use matches the Khavinson convention and reduces theoretical receptor-desensitisation concerns (though whether receptor desensitisation is even relevant to this class is unknown).

Evidence-graded hepatic stack (preferred)

If your goal is hepatic health rather than bioregulator experimentation, the evidence-weighted stack looks nothing like a Khavinson protocol. In descending order of evidence strength:

1. Weight management and alcohol reduction — highest-evidence interventions for NAFLD/NASH and alcoholic liver disease.
2. Berberine 500 mg x 2–3 daily — improves ALT/AST, hepatic steatosis, and metabolic parameters in NAFLD with RCT support.
3. Metformin 500–2000 mg daily (if insulin-resistant) — improves hepatic insulin sensitivity.
4. TUDCA 500–1500 mg daily — cholestatic biochemistry improvement with mechanistic PMID support.
5. Silymarin (milk thistle) 400–800 mg standardised daily — heterogeneous but generally positive evidence in alcoholic and viral hepatitis.
6. NAD+ precursors 300–1000 mg daily — support mitochondrial function in hepatic aging.

Livagen does not displace any tier in this stack. It is a speculative add-on if you have spare budget, not a substitute for evidence-graded care.

Hepatitis-specific considerations

If you have chronic hepatitis B or C, do not use Livagen as a substitute for direct-acting antivirals. Modern DAAs cure hepatitis C in 95%+ of patients in 8–12 weeks. Chronic hepatitis B has tenofovir/entecavir suppressive regimens. An experimental bioregulator cannot replace these therapies, and delaying them to try Livagen is actively harmful.

NAFLD/NASH considerations

If you have fatty liver disease on imaging or biopsy, the evidence hierarchy is weight loss (7–10% body weight reduction reverses steatosis in most patients), GLP-1 agonists (Semaglutide, Tirzepatide), pioglitazone, and vitamin E (specific populations). Livagen is not in this hierarchy. Adding it to a proven regimen is low-downside; substituting it for the proven regimen is not rational.

With other peptide bioregulators

Cycling Livagen with other Khavinson tetrapeptides is the dominant bioregulator-community pattern. Epitalon, Pinealon, Thymogen, Vilon, Cartalax, Prostamax all sit within the same framework. There is no evidence of harm from combining them at Khavinson-convention doses; there is also no evidence of synergy beyond a theoretical framework.

With GLP-1s and metabolic therapies

Livagen does not meaningfully interact with GLP-1 agonists, metformin, or pioglitazone. If you are on a metabolic programme for NAFLD, running a Livagen cycle as an adjunct is unlikely to harm it, unlikely to help substantially, and not a substitute for the proven intervention.

Against contraindicated combinations

Do not combine Livagen with active hepatic chemotherapy, immunosuppressive hepatitis therapy you are in the middle of, or experimental hepatology protocols without your hepatologist's knowledge. The theoretical (unvalidated) chromatin-modulation claim is not a space to experiment in the middle of a controlled protocol.

Dosage Notes

Livagen's dosing conventions come from Khavinson-group Russian publications and post-Soviet commercial product labelling. They are not derived from modern pharmacokinetic studies in humans.

Oral/sublingual dosing (commercial capsule form)

The dominant commercial format is the 20 mg oral capsule. These capsules contain an undisclosed amount of actual KEDA peptide — historical reports suggest 2–4 mg — with the balance as excipients. Standard convention:

• 1 capsule (20 mg nominal) once daily
• Sublingual administration preferred — hold under tongue for 60 seconds to permit some buccal absorption before swallowing
• Empty stomach — 30–45 minutes before first meal of the day
• Duration: 10 consecutive days per cycle
• Washout: 60–90 days between cycles

Subcutaneous dosing (research-chemical synthetic peptide)

For users obtaining synthetic KEDA peptide in lyophilised form from research-peptide suppliers:

• Dose range: 2–5 mg subcutaneous once daily
• Injection site: Subcutaneous abdomen or thigh, rotating sites
• Duration: 10 consecutive days per cycle
• Washout: 60 days minimum between cycles

Subcutaneous administration bypasses first-pass hydrolysis in the gut and hepatic portal vein, producing theoretically higher systemic exposure per milligram. Actual pharmacokinetic studies quantifying this difference have not been published in English-indexed literature.

Intranasal dosing

Not a conventional route for Livagen in published literature. Some community users attempt intranasal administration based on the precedent of Semax and Selank (both intranasal-approved in Russia), but there is no Khavinson-group convention for Livagen intranasal use and no pharmacokinetic support for this route.

Cycling rationale

The 10-days-on / 60-days-off pattern is the Khavinson convention applied uniformly across his tetrapeptide family. The rationale offered is that short peptide pulses produce sustained transcriptional adjustments that do not require continuous dosing, and that continuous dosing might produce tolerance or off-target chromatin effects. This rationale is theoretical. There is no dose-ranging or duration-comparison study establishing that 10 days is optimal versus 5 or 20 days.

Do not exceed

There is no established maximum dose. The Russian literature uses 20 mg oral consistently; higher doses have not been published. Do not exceed 20 mg oral or 5 mg SC per day without a clinical reason and supervision.

Do not continue continuously

Do not run continuous (365-day) cycles. The safety of continuous dosing has not been characterised. The published Russian protocol is always cyclical.

Age-based adjustments

Russian studies typically enrol older adults (60+). Younger adults experimenting with bioregulators should consider whether the "age-related restoration" rationale applies — if you are 30 years old with normal hepatic biochemistry, the theoretical benefit is smaller. There is no paediatric use.

Renal impairment

No formal dose adjustment is published. The peptide is small and presumably cleared via hydrolysis and renal excretion of amino-acid metabolites. If you have significant renal impairment, avoid use until modern pharmacokinetic data exist.

Hepatic impairment

This is the indication Russian practitioners use Livagen for, which does not make it safe in advanced hepatic disease. If you have Child-Pugh B or C cirrhosis, advanced NASH with fibrosis, or any cause of decompensated liver disease, do not substitute Livagen for hepatology care.